“Low-dose” growth hormone therapy during peritoneal dialysis or following renal transplantation

Abstract

The minimal effective dose of growth hormone (GH) to promote growth in children on dialysis or following renal transplantation remains unsettled. In order to study the issue, “low-dose” GH was administered to children with end-stage renal disease (ESRD) receiving chronic automated peritoneal dialysis (APD,n = 6, 4 males, 2 females) or following renal transplantation (T,n = 9, 8 males, 1 female). No APD patient was GH deficient, while 1 T patient (no. 2) had data consistent with GH deficiency, although he was obese (body mass index = 34 kg/m²). The mean dose of GH after 6 and 12 months of treatment was 0.16±0.02 and 0.22±0.07 versus 0.16±0.03 and 0.27±0.21 mg/kg per week for APD and T patients, respectively. When analyzing all patients, there were no significant differences before or after 6 and 12 months of GH therapy within or between the two groups, in terms of height velocity, bone age, renal function (in the T group) and height Z-scores (Z-Ht). However, the height velocity Z-score (Z-HV) increased significantly at 6 and 12 months compared with baseline in the APD patients only (P < 0.05). When the 2 T patients with the most impaired renal function were excluded from the analysis, Z-HV also increased significantly in the T patients after 12 months of GH (P < 0.02). We conclude that following “low-dose” GH therapy, children with ESRD treated with APD or T have similar increases in HV, allowing maintenance of Z-Ht but not “catch-up” growth.